Two U.S. biotech firms, Akston Biosciences and OKAVA Pharmaceuticals, are conducting clinical trials for GLP-1 therapies aimed at reducing obesity in cats, a significant health issue affecting 61% of cats in the U.S. These trials represent a shift in pet care, as owners increasingly invest in premium nutrition and health products.
Analysts suggest that while the market for pet obesity drugs may not mirror the success of human GLP-1 drugs, it reflects a broader trend towards medicalization in the $200 billion pet economy. Major pet food companies like Nestlé are already adapting their strategies to focus on health and longevity, indicating a growing convergence between nutrition and veterinary medicine.
However, the affordability of these treatments will be crucial for widespread adoption among pet owners, as many are concerned about costs compared to human medications. The outcome of these trials and the subsequent market response could significantly impact the future of pet healthcare